NXL: Nexalin Technology, Inc. Stock

by  •  • Comments Off on NXL: Nexalin Technology, Inc. Stock

SIC 3845 – Electromedical and Electrotherapeutic Apparatus

Valuation
Market Cap ($M) 10.34
Enterprise Value ($M) 10.26
Book Value ($M) 3.21
Book Value / Share 0.43
Price / Book 3.22
NCAV ($M) 3.00
NCAV / Share 0.40
Price / NCAV 3.44

Profitability (mra)
Return on Invested Capital (ROIC) -1.25
Return on Assets (ROA) -0.78
Return on Equity (ROE) -0.98

Liquidity (mrq)
Quick Ratio 7.70
Current Ratio 8.07

Balance Sheet (mrq) ($M)
Current Assets 3.43
Assets 3.63
Liabilities 0.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.11
Operating Income -5.70
Net Income -4.65

Cash Flow Statement (mra) ($M)
Cash From Operations -3.84
Cash from Investing 4.45
Cash from Financing -0.20

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTIO
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SE
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 19,239 71,613 26.87
2024-04-25 11,817 13,312 88.77
2024-04-24 2,551 12,344 20.67
2024-04-23 22,110 8,372 264.09

(click for more detail)

Similar Companies
NUWE – Nuwellis, Inc. NVNO – enVVeno Medical Corporation
NXGL – NEXGEL, Inc. PAVM – PAVmed Inc.
PDEX – Pro-Dex, Inc.


Financial data and stock pages provided by
Fintel.io